MindWalk Q1 Earnings Call Highlights

Key Points

• First-quarter revenue rose 21% year over year to CAD 3.8 million, while gross margin improved to 59%. However, the net loss widened to CAD 6.1 million as sales, marketing, R&D and administrative expenses increased.
• MindWalk is pursuing larger, multi-year ReefIQ enterprise agreements with major pharmaceutical companies, but negotiations may take time due to security, data governance, legal and procurement reviews. Initial contracts could produce uneven, milestone-driven revenue before transitioning to recurring revenue.
• The company is shifting toward platform partnerships that may include upfront payments, milestones and royalties; about 80% of its commercial funnel by value uses this model. MindWalk also secured a commitment for a US$30 million revolving credit facility at a fixed 7% rate, subject to final documentation.

MindWalk NASDAQ: HYFT reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model.

Gross margin increased to 59% from 48% in the prior-year quarter. However, the company’s net loss from continuing operations widened to CAD 6.1 million from CAD 4.1 million, reflecting higher spending on sales, marketing, research and development, and general and administrative activities.

President and Chief Executive Officer Jennifer Bath said the company is pursuing enterprise adoption of ReefIQ, which launched in June. She described the platform as a layer that converts complex, unstructured biological data into structured representations intended to help artificial intelligence models produce more actionable insights for pharmaceutical customers.

ReefIQ Enterprise Discussions Underway

Bath said MindWalk is engaged with multiple large pharmaceutical companies regarding potential enterprise deployments of ReefIQ, though she did not identify partners, contract values, or expected closing dates.

“These opportunities are substantially larger than our historical LensAI recurring revenue agreements,” Bath said, adding that investors should not use prior LensAI contracts as a benchmark for the potential size or scope of ReefIQ arrangements.

According to Bath, ReefIQ is designed to generate multi-year recurring revenue as customers expand their use of the platform within biological data systems and discovery workflows. The company’s existing client base includes 19 of the top 20 global pharmaceutical companies, she said.

During the question-and-answer session, Bath outlined several factors affecting the pace of enterprise negotiations. These include information technology security, data governance and data residency reviews; legal and procurement negotiations for multi-year platform agreements; and defining the programs and data domains included in an initial deployment.

“None of them are really about whether or not the platform works,” Bath said of the review processes. She noted that enterprise customers are bringing MindWalk into their core data infrastructure, often across multiple jurisdictions.

Chief Financial Officer Scott Areglado said initial ReefIQ arrangements could create uneven revenue patterns because they may include upfront engineering work and milestone-based payments before transitioning to annual recurring revenue.

“These initial ReefIQ agreements are probably going to be relatively lumpy,” Areglado said. “It really just depends on how quickly we get adoption of ReefIQ.”

Shift Toward Platform Partnerships

MindWalk is also restructuring commercial relationships with pharmaceutical customers, increasingly pursuing broader platform partnerships rather than discrete fee-for-service projects. Under those arrangements, the company expects to participate in the economics of assets it helps create through upfront payments, milestones and royalty-based components.

Bath said roughly 80% of the company’s current commercial funnel by value is structured as such partnerships, spanning data management, ReefIQ and multi-target discovery work.

She said the change means every new client discussion now includes a partnership structure, rather than solely a fee-for-service option. Bath acknowledged that the approach can lengthen negotiations but said customers have continued engaging with the company.

The company has spent years demonstrating its ability to advance biologic drug candidates, Bath said. MindWalk stated that its work has contributed to several dozen molecules reaching clinical testing, with 10 currently in Phase 1 through Phase 3 trials and four characterized as first-in-class molecules.

Bath also said MindWalk has increasingly integrated its wet-lab capabilities with in silico work, generating data sooner for client decision-making and exposing customers to LensAI subscriptions and applications.

Financial Results and Spending

• Revenue rose approximately CAD 673,000 year over year to CAD 3.8 million.
• Gross profit was CAD 2.2 million, compared with CAD 1.5 million a year earlier.
• Research and development expense increased to CAD 1.3 million from CAD 1 million, primarily due to higher salary costs supporting commercial platform development.
• Sales and marketing expense rose to CAD 3.2 million from CAD 1.3 million, driven by increased commercial headcount, advertising and promotion investments.
• General and administrative expense increased to CAD 3.9 million from CAD 3.3 million, primarily due to non-cash stock-based compensation.

Areglado said the first quarter represented MindWalk’s fifth consecutive quarter of year-over-year revenue growth. He also noted that the prior-year period included CAD 1.1 million of income from discontinued operations, resulting in an overall net loss of CAD 3 million in that period.

Credit Facility and Infrastructure Progress

MindWalk ended the July 31 quarter with CAD 7.6 million in cash, down from CAD 11.3 million on April 30. Net cash used in operating activities was CAD 4 million, compared with CAD 4.2 million in the prior-year quarter.

The company also announced a binding commitment for a US$30 million senior unsecured revolving credit facility with a fixed 7% interest rate. Bath said the facility can be drawn as needed and is intended to provide financial flexibility without issuing equity.

Areglado said MindWalk has 60 days to finalize the credit agreement and cannot draw on the facility until the agreement is complete. He added that the company expects to access the capital as liquidity needs arise and that it retains cash on hand.

Management said the revolving facility does not replace the company’s planned ring-fenced financing structure for certain assets in its Cayman structure. Bath said the company remains in discussions with interested parties and is approximately 90% to 95% through the associated legal and tax planning work.

Separately, MindWalk said it validated a production deployment of OpenFold3 using AMD Instinct MI325X graphics processing units with engineering partner AMD and Vultr. Bath said the results were being published during the week of the call and that the deployment expands the company’s ability to run discovery workloads and scale ReefIQ.

About MindWalk (NASDAQ:HYFT)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.